Navigation Links
Immtech to be Listed on OTC Market
Date:5/21/2009

ries. For additional information, please visit the Company's website at http://www.immtechpharma.com.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts, are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2008 filed on June 18, 2008, and in its other SEC filings and include, but are not limited to: (i) conditions in the credit markets and the general economy; (ii) Immtech's ability to obtain additional funds; (iii) Immtech's ability to manage its remaining resources; (iv) Immtech's ability to continue as a going concern; (v) Immtech's ability to retain key personnel; (vi) the ability of Immtech's scientists and collaborators to discover new compounds; (vii) the availability of additional research grants; (viii) Immtech's ability to obtain regulatory approval of its drug candidates; (ix) the success of Immtech's clinical trials; (x) dependence upon and contractual relationship with partners; (xi) Immtech's ability to protect its intellectual property; and (xii) competition and alternative technologies.

In addition, Immtech does not undertake any obligation, and specifically disclaims any obligation to publicly update or revise forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.


'/>"/>
SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Immtech Completes Malaria Prevention Trial
2. Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
3. Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
4. Immtech Investor Conference Call Scheduled for February 22, 2008
5. Immtech Announces Update on Business Operations
6. Immtech Announces Results From Hepatitis C Discovery Program
7. Immtech Reports Fiscal Year End 2008 Results
8. Immtech Investor Conference Call Scheduled for June 25, 2008
9. Immtech Reports Fiscal Second Quarter 2009 Results
10. Immtech Receives Listing Notice From NYSE Alternext US
11. Immtech Announces Sale of Property Subsidiary in China

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ches EyeCentral Remote Video Platform for the Secu...e for Central Stations and Security Dealers. , ...er 24, 2009 -- NCL Security Launches EyeCentral Re...enerate Recurring Monthly Revenue for Central Stat...curity systems has been and still is a great trend...
(Date:11/24/2009)...wire/--Newpeer-revieweddatafindingthatfewerthanone...nichepatitisCvirushavereceivedanti-viraltherapyinr...oveurgentlyonbipartisanlegislationtosupportnewstat...he NationalViralHepatitisRoundtable(NVHR) saidtoda...n,millionsofAmericansinfectedwithchronichepatitisC...
(Date:11/23/2009)...an determined that only 663,000 of the approximate...CV) infection received antiviral therapy between 2...ing, in part because only half of the patients kno...tinues, by 2030 less than 15% of liver-related dea...y. This study, the first to analyze nationwide pr...
(Date:11/23/2009),, NEWYORK,Nov.23/PRNewswire/--Livingwithchronicpaincanbedifficult-andthestressoftheholidayseasoncanprovetobequitechallengingforthoselivingwithpain. ,, ListentothisreportfromPfizerInc.at: ,
(Date:11/23/2009)...igh cost of drug advertising that does little to b...ersity of British Columbia health policy researche...s of Internal Medicine , examined the US sales pat...n by the trade name Plavix used to prevent blood c...lected to study the impact of advertising on sales...
Breaking Medicine News(10 mins):Health News:NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers 2Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 2Health News:Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US 2Health News:Drug ads ineffective for boosting sales, could cost taxpayers: UBC-Harvard study 2
...o the combination of just two genes, according to ...rne.The research, published in the Journal of Clin...ntifies one gene on chromosome 15 and one on the Y...oth of these genes you will be taller than a perso...
... used to kill the deadly Hepatitis E virus has bee...been designed using the viral clones and would kil...acy of the ribozyme was being tested on animals. T...ecombinant viral proteins which could be used to g...
...don't forget whole grains, if you want to cut your...r, researchers say.// Fruits and vegetables espe...flower and cabbage - can reduce stroke risk by abo... 30% to 40% less likely to have an ischemic (block...
... have found that treadmill testing is a useful way...any people who develop// heart disease have no obv...ccording to researchers, treadmill testing can sho...ing and then followed up for 20 years. In the trea...
...nt osteoporosis. The research involves a drug call...ancer patients to treat a condition in which calci...w the rate of bone less and increase bone density,...years before doctors know whether the drug really ...
...s issued new recommendations telling pediatricians...ld be a sign of a serious illness. Children who sn...oea syndrome (OSAS). Left untreated, the disorder ...doctors to ask whether the child snores. If the an...
Other Medicine News:
(Date:11/23/2009)...ll/--NuVasive, Inc. (Nasdaq: NUVA ),amedicaldevice...uptivesurgicaltreatmentsforthespine,announcedtoday...andMichaelJ.Lambert,ExecutiveVicePresidentandChief...ualPiperJaffrayHealthCareConferenceattheNewYorkPal...10:00a.m.ET.Mr.LukianovandMr.Lambertarealsoschedul...
(Date:11/23/2009)...rstCall/--WestPharmaceuticalServices,Inc.(NYSE: WS...icerMatthewT.Mullarkeyhasleftthecompanybymutualagr...cerStevenA.Ellers,58,willdeferhispreviouslyannounc...tyandsupportfollowingMr.Mullarkey,sdeparture. ,...ponentsandsystemsforinjectabledrugdelivery,includi...
(Date:11/23/2009)...ire-FirstCall/--BeckmanCoulter,Inc.(NYSE: BEC ),al...thatsimplify,automate,andinnovatecomplexbiomedical...er,svicepresidentofstrategy,willpresentatthePiperJ...09at12:00p.m.(ET). ,, (Logo: http://www.newscom...webcastofBeckmanCoulter,spresentationcanbeaccessed...
Breaking Medicine Technology:NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference 2NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference 3New Fertility Financing for Donated Eggs Fills Void Left by Capital One 51716 1New Fertility Financing for Donated Eggs Fills Void Left by Capital One 51716 2Urban Caucus Chair Says Healthcare Reform Means You Can Have Your Care and Keep It Too 51714 1Urban Caucus Chair Says Healthcare Reform Means You Can Have Your Care and Keep It Too 51714 2Solta Medical Inc Announces Second Quarter 2009 Results Release Date and Conference Call 51711 1Solta Medical Inc Announces Second Quarter 2009 Results Release Date and Conference Call 51711 2
...ith FDA, WALTHAM, Mass., Feb. 22 Arbios Systems,...hat the Company has received,conditional approval ... of,an Investigational Device Exemption ("IDE") to...rbios, extracorporeal (outside the body) artificia...ronically ill patients,suffering from acute liver ...
...ly-held,medical device company and maker of the Ve...sponse to antiplatelet drugs, announced today that...cing. The syndicate was led by,Arnerich Massena & ...ting,in the round were previous investors: Essex W...B Partners and Kaiser Permanente Ventures., "We f...
Other Medicine Technology:Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 2Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 3Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 4Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial 2
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
Medicine Products: